Kathryn Arbour, MD, on the Development of KRAS G12C Inhibitors in Lung Cancer

Kathryn Arbour, MD, from Memorial Sloan Kettering Cancer Center, discusses exciting advancements in the field of immunotherapy for treating lung cancer – in particular, the development of KRAS G12C inhibitors in early-phase clinical trials – at the Annual New York Lung Cancers Symposium®.

Transcription:
So, I think I’m really excited about new treatments for immunotherapies that are both combinations or understanding the mechanisms of resistance to immunotherapy medicines. I think the other category of treatments that are most exciting in lung cancer are new targeted therapies that we haven’t had before – both emerging from clinical trials that are promising and other agents that are really early in clinical development. For example, KRAS G12C inhibitors, which is a big category of patients in a large number, probably 12%-14% of lung cancer patients have a KRAS G12C mutation, and we’ve never had drugs for these patients that have been effective in early clinical trials or showing any exciting promise in that field, so I’m looking  forward to seeing how that goes moving forward in the future and where we will fit these agents into therapies for our patients.